Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab

Rheumatology

Volumn 47, Issue 4, 2008, Pages 552-553

  McGonagle, D ^a,b   Tan, A L ^b   Madden, J ^a   Rawstron, A C ^b   Rehman, A ^a   Emery, P ^b   Thomas, S ^a  

^a CALDERDALE ROYAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; CLINICAL FEATURE; COR PULMONALE; ELECTROCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LYMPHOCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; SCLERODERMA; THORAX RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; MIDDLE AGED; SYSTEMIC SCLEROSIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 43049159803     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem357     Document Type: Letter

References (10)

1. Edwards JC, Szczepañski L, Szechiñski J et al. Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
2. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001; 40:205-11.
3. Levine TD. Rituximab in the treatment of dermatomyositis: An open-label pilot study. Arthritis Rheum 2005;52:601-7.
4. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibodyassociated vasculitis. Arthritis Rheum 2005;52:262-8.
5. Giagounidis AA, Anhuf J, Schneider P et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: A pilot study. Eur J Haematol 2002;69:95-100.
6. Fujimoto M, Sato S. B Lymphocytes and systemic sclerosis. Curr Opin Rheumatol 2005;17:746-51.
7. Wollheim FA. Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel? Arthritis Rheum 2007;56:9-12.
8. Adams AB, Barillas-Arias L, Angeles ST, MacDermott EJ, Barinstein L, Lehman TJA. Cyclophosphamide and rituximab combination therapy for the treatment of juvenileonset scleroderma: 6 Patient Case Series. Proceedings of ACR/ARHP Annual Scientific Meeting 2006, Washington, DC, USA, November 10-15.
9. Farge D, Passweg J, van Laar JM et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: Report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974-81.
10. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006;3:e297.